Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

dc.contributor.authorZugasti, Inés
dc.contributor.authorTormo Ratera, Marta
dc.contributor.authorOliver Caldés, Aina
dc.contributor.authorSoler Perromat, Juan Carlos
dc.contributor.authorGonzález Calle, Verónica
dc.contributor.authorMoreno Fajardo, David Fernando
dc.contributor.authorCabañas, Valentín
dc.contributor.authorLópez Muñoz, Nieves
dc.contributor.authorBartolomé Solanas, Álvaro
dc.contributor.authorEspañol Rego, Marta
dc.contributor.authorReguera Ortega, Juan Luis
dc.contributor.authorRosiñol Dachs, Laura
dc.contributor.authorLópez Corral, Lucía
dc.contributor.authorTovar Gomis, Natalia
dc.contributor.authorRodríguez Lobato, Luis Gerardo
dc.contributor.authorAlvarez Perez, Rosa María
dc.contributor.authorVarea, Sara
dc.contributor.authorOlesti Muñoz, Eulàlia
dc.contributor.authorGómez Grande, Aldofo
dc.contributor.authorFrutos, Laura
dc.contributor.authorTamayo, Pilar
dc.contributor.authorJuan, Manel
dc.contributor.authorUrbano Ispizua, Álvaro
dc.contributor.authorMoraleda, José María
dc.contributor.authorGonzález Navarro, E. Azucena
dc.contributor.authorMartínez López, Joaquín
dc.contributor.authorMateos, María Victoria
dc.contributor.authorTomás Batlle, Xavier
dc.contributor.authorSetoain Perego, Xavier
dc.contributor.authorFernández de Larrea, Carlos José
dc.date.accessioned2026-10-23T13:29:16Z
dc.date.available2026-10-23T13:29:16Z
dc.date.issued2025-02-11
dc.date.updated2026-10-23T13:29:16Z
dc.description.abstractMultiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. This study included 63 patients with relapsed/refractory MM treated either in the CARTBCMA-HCB-01 clinical trial (ARI0002h; academic B-cell maturation antigen [BCMA]–targeted CAR T-cell therapy) or in compassionate use. The aim was to evaluate the impact of soft-tissue involvement (extramedullary [EMD] and paraskeletal [PS] plasmacytomas) in response, survival and safety. Baseline [18F]fluorodeoxyglucose (FDG)–positron emission tomography (PET)/computed tomography (CT) from 5 participating centers were reviewed centrally. Of 63 patients, 52.4% presented plasmacytomas at the time of inclusion (21 PS, exclusively; and 12 EMD). Per responses, there were no significant differences between patients with and without plasmacytomas. A correlation was present between International Myeloma Working Group responses and those obtained by [18F]FDG-PET/CT at day 100 (Bologna criteria). No differences were observed in progression-free survival (PFS) or overall survival (OS) between patients with or without plasmacytomas. However, both PFS and OS were significantly shorter in patients with EMD. Interestingly, [18F]FDG-PET/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of ≥25 cm3 at baseline [18F]FDG-PET/CT was associated with earlier disease progression and shorter OS. These results highlight the importance of EMD evaluation by [18F]FDG-PET/CT before and after CAR T-cell infusion. This trial was registered at www.ClinicalTrials.gov as #NCT04309981; and EudraCT, 2019-001472-11.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec767064
dc.identifier.idimarina9462430
dc.identifier.issn2473-9529
dc.identifier.pmid39602341
dc.identifier.urihttps://hdl.handle.net/2445/232302
dc.language.isoeng
dc.publisherAmerican Society of Hematology
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2024014360
dc.relation.ispartofBlood Advances, 2025, vol. 9, num.3, p. 571-582
dc.relation.urihttps://doi.org/10.1182/bloodadvances.2024014360
dc.rightscc-by-nc-nd (c) American Society of Hematology, 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.classificationMieloma múltiple
dc.subject.classificationImmunoteràpia
dc.subject.classificationCèl·lules T
dc.subject.otherMultiple myeloma
dc.subject.otherImmunotheraphy
dc.subject.otherT cells
dc.titleClinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
923095.pdf
Mida:
2.76 MB
Format:
Adobe Portable Document Format